{"id":50300,"date":"2025-06-24T13:17:20","date_gmt":"2025-06-24T11:17:20","guid":{"rendered":"https:\/\/www.maiwald.eu\/presseberichte\/maiwald-advises-royalty-pharma-on-2-billion-funding-agreement-with-revolution-medicines\/"},"modified":"2025-06-24T13:17:20","modified_gmt":"2025-06-24T11:17:20","slug":"maiwald-advises-royalty-pharma-on-2-billion-funding-agreement-with-revolution-medicines","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/ko\/press-coverage\/maiwald-advises-royalty-pharma-on-2-billion-funding-agreement-with-revolution-medicines\/","title":{"rendered":"Maiwald Advises Royalty Pharma on $2 Billion Funding Agreement with Revolution Medicines"},"content":{"rendered":"\n<p>Maiwald acted as legal advisor to <strong>Royalty Pharma<\/strong> in connection with an innovative funding agreement totaling up to <strong>$2 billion<\/strong> with <strong>Revolution Medicines<\/strong>. The transaction includes up to <strong>$1.25 billion<\/strong> in synthetic royalty funding and a <strong>secured term loan of up to $750 million<\/strong>.<\/p>\n\n\n\n<p>This strategic partnership enables Revolution Medicines to independently advance and globally commercialize <strong>daraxonrasib<\/strong>, a potentially game-changing RAS(ON) inhibitor currently in <strong>Phase 3 clinical trials<\/strong> for <strong>pancreatic cancer<\/strong> and <strong>non-small cell lung cancer (NSCLC)<\/strong>. If successful, daraxonrasib could become the first targeted therapy to inhibit all major forms of RAS \u2014 one of the most common drivers of human cancers.<\/p>\n\n\n\n<p>The agreement highlights Royalty Pharma\u2019s ability to deliver flexible, large-scale capital solutions to innovative biotech companies while allowing them to retain full control over development and commercialization.<\/p>\n\n\n\n<p>We are proud to have supported Royalty Pharma on this milestone transaction. This text is a summary of an article published by Royalty Pharma. The full text of the article is available\u00a0<a href=\"https:\/\/www.royaltypharma.com\/news\/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion\/\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-50300","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/presseberichte\/50300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":0,"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/presseberichte\/50300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/ko\/wp-json\/wp\/v2\/media?parent=50300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}